EVALUATION OF Xpert MTB/RIF RESULTS AND ANTIBIOTIC SUSCEPTIBILITY RATES IN MYCOBACTERIUM TUBERCULOSIS COMPLEX ISOLATES:FOUR YEARS FOLLOW UP

INTRODUCTION AND AIM: Rapid and accurate diagnosis of Mycobacterium tuberculosis is crucial to start treatment rapidly and prevent new infections. TheXpertMTB/RIF assay(Cepheid,USA), the only WHO-approved rapid molecular test for initial TB diagnosis, is widely used in TB laboratories in our country...

Full description

Saved in:
Bibliographic Details
Main Authors: Gizem Niğdelioğlu, Elvan Sayın, Barış Can, Arzu Ilki
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Journal of Global Antimicrobial Resistance
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2213716524002819
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:INTRODUCTION AND AIM: Rapid and accurate diagnosis of Mycobacterium tuberculosis is crucial to start treatment rapidly and prevent new infections. TheXpertMTB/RIF assay(Cepheid,USA), the only WHO-approved rapid molecular test for initial TB diagnosis, is widely used in TB laboratories in our country. This study aims to evaluate the Mycobacterium tuberculosis XpertMTB/RIF test results and assess the susceptibility of Mycobacterium tuberculosis complex(MTC) strains to first-line antituberculosis drugs in our hospital. MATERIALS-METHODS: XpertMTB/RIF, M.tuberculosis culture and antibiotic susceptibility results were evaluated for 4 years between January 2020 and 2024. Samples were processed by PCR testing with XpertMTB/RIF and cultured on Löwenstein-Jensen medium and BACTECMGIT960system. MTC identification and drug susceptibility testing for streptomycin(SM),isoniazid(INH),rifampicin(RIF), and ethambutol(ETM) were performed according to standard protocols. RESULTS: A total of 14,544 samples were evaluated, including 5,682 for MTC-PCR. Of the samples, 7536(51.8%) were respiratory samples. MTC-DNA was detected in 157(4.8%) respiratory and 68(2.8%) non-respiratory samples.(Table 1) Culture confirmed MTC in 58.4% of PCR-positive respiratory samples and 47% of PCR-positive non-respiratory samples. Anti-TB drug susceptibility testing showed that 76.1% of 178 isolates were susceptible to all drugs tested, while 23.0% were resistant to at least one drug, including two MDR-TB cases(Table 2).Anti-TB drug susceptibility testing confirmed Rifampicin resistance in 2 isolates in which Rifampicin resistance was detected using XpertMTB/RIF. CONCLUSION: The Xpert MTB/RIF assay is highly sensitive and specific for rapid TB diagnosis and drug resistance detection. However, culture results and clinical correlation are essential for diagnosing active disease. Regular monitoring of drug resistance is critical.
ISSN:2213-7165